AvKARE, Inc. – Trademark Portfolio

Entity Type: 03

AvKARE, Inc. owns a portfolio of 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as AVPAK, AV PAK, and AVKARE. Of these, 5 are registered. The portfolio spans 3 Nice Classification classes, led by Class 5 (Pharmaceuticals) and Class 35 (Advertising & Business). Headquartered in Pulaski, TN.

615 North First Street

Pulaski, TN 38478

11 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

AvKARE, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

35
Advertising & Business (4 filings)

Advertising; business management; business administration; office functions

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does AvKARE, Inc. have?

AvKARE, Inc. has 11 U.S. trademarks filed with the USPTO. Of these, 5 registered, 5 abandoned, 1 cancelled.

What trademark classes does AvKARE, Inc. file in?

AvKARE, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are AvKARE, Inc.'s most well-known trademarks?

AvKARE, Inc.'s registered trademark portfolio includes well-known marks such as AVPAK, AV PAK, and AVKARE. These are among 5 currently registered trademarks in the portfolio.

What is AvKARE, Inc.'s trademark registration success rate?

AvKARE, Inc. has a 45% trademark registration rate, with 5 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.